QANDLI DIABET BILAN OG‘RIGAN BEMORLARDA KO‘KRAK BEZI SARATONINING RIVOJLANISH XAVFI VA PROGNOZIGA TA’SIRI
Keywords:
qandli diabet, 2-tur diabet, ko‘krak bezi saratoni, onkologik kasalliklar, metabolik buzilishlar, insulin rezistentligi, giperglikemiya, IGF-1 (insulin-o‘xshash o‘sish omili), surunkali yallig‘lanish, oksidativ stress, epidemiologik tadqiqotlar, meta-tahlil, nisbiy xavf (RR), hazard ratio (HR), prognoz, ayollar salomatligiAbstract
Ko‘krak bezi saratoni ayollar orasida eng keng tarqalgan onkologik kasalliklardan biri bo‘lib, global miqyosda yuqori kasallanish va o‘lim ko‘rsatkichlari bilan tavsiflanadi. So‘nggi yillarda metabolik kasalliklar, xususan qandli diabetning saraton rivojlanishidagi o‘rni tobora oshib bormoqda. Ushbu tadqiqotning maqsadi qandli diabet bilan og‘rigan bemorlarda ko‘krak bezi saratoni rivojlanish xavfi va uning prognoziga ta’sirini aniqlashdan iborat.Tadqiqotda PubMed, Scopus va Google Scholar ma’lumotlar bazalarida chop etilgan epidemiologik tadqiqotlar, kohort va holat-nazorat ishlari hamda meta-tahlillar natijalari oʻrganib chiqildi. Olingan ma’lumotlarga ko‘ra, qandli diabet bilan og‘rigan ayollarda ko‘krak bezi saratoni rivojlanish xavfi sog‘lom ayollarga nisbatan o‘rtacha 20–27% ga yuqori (RR≈1.20–1.27) ekanligi aniqlangan. Ayniqsa, postmenopauza davridagi ayollarda ushbu xavf yanada ortishi kuzatiladi.Shuningdek, diabet mavjudligi ko‘krak bezi saratoni bilan kasallangan bemorlarda kasallik prognoziga salbiy ta’sir ko‘rsatadi. Xususan, umumiy omon qolish ko‘rsatkichining pasayishi va o‘lim xavfining oshishi (HR≈1.49) qayd etilgan. Ushbu bog‘liqlik giperglikemiya, insulin rezistentligi, insulin va IGF-1 darajasining oshishi, shuningdek surunkali yallig‘lanish va oksidativ stress kabi patofiziologik mexanizmlar bilan izohlanadi.
Xulosa qilib aytganda, qandli diabet ko‘krak bezi saratoni rivojlanish xavfini oshiruvchi va uning klinik kechishi hamda prognozini yomonlashtiruvchi muhim omil hisoblanadi. Shu sababli, ushbu bemorlar guruhida erta diagnostika, individual yondashuv va metabolik nazoratni kuchaytirish muhim ahamiyatga ega.
References
1.Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. International Journal of Cancer. 2007;121(4):856–862.
2.Boyle P, Boniol M, Koechlin A, et al. Diabetes and breast cancer risk: a meta-analysis. British Journal of Cancer. 2012;107(9):1608–1617.
3.Peairs KS, Barone BB, Snyder CF, et al. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. Journal of Clinical Oncology. 2011;29(1):40–46.
4.Lipscombe LL, Goodwin PJ, Zinman B, et al. Diabetes mellitus and breast cancer: a retrospective cohort study. Breast Cancer Research and Treatment. 2006;98(3):349–355.
5.Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33(7):1674–1685.
6.Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocrine-Related Cancer. 2009;16(4):1103–1123.
7.Li D, Yeung SC, Hassan MM, et al. Anti-diabetic therapies affect risk of cancer. Annals of Oncology. 2009;20(5):843–847.
8.Johnson JA, Carstensen B, Witte D, Bowker SL, Lipscombe L. Diabetes and cancer (including breast cancer): a population-based study. Diabetologia. 2012;55(6):1637–1644.
9.Hartog H, Wesseling J, Boezen HM, Dullaart RPF. The association between diabetes and breast cancer prognosis. Breast Cancer Research and Treatment. 2016;160(3):483–497.
10.Onitilo AA, Stankowski RV, Berg RL, et al. Diabetes and cancer risk in the elderly. Diabetes Care. 2012;35(7):1446–1453.
11.Mayer DK, Terrin NC, Menon U, et al. Diabetes mellitus and survival in breast cancer patients. Cancer. 2007;112(3):498–505.
12.Huang J, Xie H, Wang C, et al. Diabetes mellitus and breast cancer: systematic review and meta-analysis of cohort studies. European Journal of Cancer Prevention. 2015;24(6):494–501.
